Form 4: MediWound Director Acquires Shares, Reports Holdings

MediWound Ltd. Director Samuel Rubinstein reported the acquisition of 150 ordinary shares and provided an update on his beneficial ownership of company stock.

Summary

• Samuel Rubinstein, a Director at MediWound Ltd., acquired 150 ordinary shares on May 29, 2026, at a price of $14.33 per share.
• Following this transaction, Rubinstein directly beneficially owns 2,993 ordinary shares.
• The filing also details other holdings, including 750 ordinary shares held indirectly by his spouse and 525 ordinary shares held indirectly by his spouse.
• Additionally, the report lists several stock options granted to Rubinstein with exercise prices ranging from $9.64 to $18.54, with vesting dates extending to 2036.
• Restricted Stock Units (RSUs) granted on March 4, 2026, which vest one year after the grant date, are also noted.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions and holdings without significant positive or negative financial news.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 150 shares by a director at a price of $14.33 per share indicates a direct investment in the company.
• The filing provides a comprehensive overview of the director's direct and indirect beneficial ownership, offering transparency to investors.

Negatives

• The filing does not provide context for the acquisition, such as whether it was part of a pre-arranged trading plan or a discretionary purchase.
• The number of shares acquired is relatively small in the context of total outstanding shares, limiting its immediate impact.

Risks

• The existence of numerous stock options with varying exercise prices could lead to future dilution if exercised.
• The vesting schedules for RSUs and stock options indicate potential future share issuances.

Future Outlook

The filing primarily reports on past transactions and current beneficial ownership. It does not contain specific forward-looking financial guidance. However, the details on stock options and RSUs suggest potential future share issuances tied to vesting schedules.

Management Comments

• The filing is a standard SEC Form 4 reporting beneficial ownership changes and does not contain direct management commentary.
• Explanations for specific holdings are provided, such as RSUs vesting on the one-year anniversary of the grant date.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders and provide transparency into their transactions and holdings. Such filings are crucial for investors to understand insider sentiment and potential future share supply.

Stakeholder Impact

• Shareholders gain insight into a director's investment activity and overall beneficial ownership, which can inform their investment decisions.
• The disclosure of stock options and RSUs provides information on potential future dilution, relevant to all shareholders.

Next Steps

• The director's holdings will continue to be monitored through subsequent SEC filings.
• Vesting of RSUs and stock options may lead to future changes in beneficial ownership.

Key Dates

Keywords

MediWound Ltd., MDWD, Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Stock Options, RSUs, Director Transaction, Equity Securities